Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02688517 · ClinicalTrials.gov registry record
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
A clinical trial of Malignant Neoplasm, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- 1,100
- Enrollment target
- 11
- Study locations
NCT02688517: Recruiting study of Malignant Neoplasm, sponsored by Rutgers, The State University of New Jersey.
NCT02688517 is a study of Malignant Neoplasm that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 1,100 participants, above the 495-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (122% higher). The trial reports 11 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02688517, a study of Malignant Neoplasm, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- 1,100 participants
- Enrollment target
- 11
- Study locations
Study Summary
This research trial studies the use of targeted genomic analysis of blood and tissue samples from patients with cancer. Genomic sequencing is a laboratory method that is used to determine the entire genetic makeup of a specific organism or cell type. Genomic sequencing can be used to find changes in areas of the genome that may be important in the development of cancer. It may also help doctors improve ways to diagnose and treat patients with rare cancers with poor prognosis or lack of effective therapy.
Primary Outcome
Descriptive analysis will be used to determine frequencies of specific mutations and to determine the pathways that can be targeted most frequently in patients with rare/poor prognosis cancer.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Cytology Specimen Collection Procedure
Study Locations (11)
New Jersey
- Ocean Medical Center - Brick
- Bayshore Community Hospital - Holmdel
- RWJBarnabas Health - Jersey City Medical Center, Jersey City - Jersey City
- Southern Ocean County Medical Center - Manahawkin
- Morristown Medical Center - Morristown
- Jersey Shore Medical Center - Neptune City
- Rutgers Cancer Institute of New Jersey - New Brunswick
- Riverview Medical Center/Booker Cancer Center - Red Bank
- Riverview Medical Center - Red Bank
- Overlook Hospital - Summit
Wisconsin
- University of Wisconsin Hospital and Clinics - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2013-02 |
| Est. Completion | 2030-05 |
What NCT02688517 shows while recruiting
NCT02688517 is an observational study that tracks outcomes without assigning an intervention. Its 1,100 participants enrollment target places it among the larger protocols in the corpus, above the 495-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (122% higher).
The record links to 1 condition, with Malignant Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02688517 lists 11 locations in 2 states (New Jersey, Wisconsin).
Frequently Asked Questions
What is clinical trial NCT02688517 about?
NCT02688517 is a clinical study titled "Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer". This research trial studies the use of targeted genomic analysis of blood and tissue samples from patients with cancer. Genomic sequencing is a laboratory method that is used to determine the entire genetic makeup of a specific organism or cell type. Genomic sequencing can be used to find changes in...
What is the current status of trial NCT02688517?
This trial is currently recruiting. The enrollment target is 1,100 participants. The study started on 2013-02. Estimated completion is 2030-05.
What conditions does trial NCT02688517 study?
This clinical trial studies the following conditions: Malignant Neoplasm.
What interventions are being tested in trial NCT02688517?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Cytology Specimen Collection Procedure (OTHER).
Who is sponsoring clinical trial NCT02688517?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02688517 being conducted?
This trial has 11 study locations across New Jersey, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02688517's enrollment target sits among peer trials
1,100 4th of 59 higher than 56 of 59 other Malignant Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
RECRUITING · Phase 1
-
Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases
RECRUITING · Phase 3
-
Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer
RECRUITING
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
RECRUITING · NA
-
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
- NCT06066502 · 1,100 participants · Phase 3
Precision Ventilation vs Standard Care for Acute Respiratory Distress Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia